Cleaning Validation Procedure for Sterile Injectables (Parenterals)
A working procedure for validating the cleaning of equipment used to make injectable products, where the final rinse is WFI, endotoxin and bioburden are acceptance criteria alongside chemical residue, and the limits tend to be the tightest in the series.
01Purpose and scope
The purpose of this procedure is to give documented evidence that the approved cleaning procedure removes active residue, cleaning agent, endotoxin and microbial contamination from sterile product equipment to levels that are safe for a product injected into patients.
The scope covers shared product-contact equipment through the sterile process: compounding and holding tanks, transfer lines and pipework, sterilizing filter housings, filling pumps, tubing and needles, and the lyophilizer where one is used. Each injectable has to be non-pyrogenic, and endotoxin contamination can result from poor control, so endotoxin is treated as a cleaning criterion in its own right.8
Three things set parenterals apart. The route of administration puts the previous product's residue straight into the bloodstream or tissue, so limits are tighter. The rinse water must meet WFI specifications for the final rinse of parenteral equipment.8 And cleaning is followed by sterilization, so the validated state covers chemical, microbial and pyrogen aspects together. Read the tablets and oral liquids posts first if the MACO method is new to you.
Sterile Drug Products: Formulation, Packaging, Manufacturing, and Quality — Michael J. Akers
A comprehensive volume on sterile products in the Drugs and the Pharmaceutical Sciences series, covering how injectable products are formulated, filled and controlled, alongside the quality and packaging topics that surround them.
It supplies the process knowledge behind this procedure: knowing how a sterile product moves from compounding through filtration to filling and freeze-drying tells you which surfaces carry product, and where residue, bioburden and endotoxin can collect.
02Regulatory basis
| Document | Body | What it contributes |
|---|---|---|
| Guide to Inspections of Validation of Cleaning Processes (1993) | U.S. FDA | Expects a written, scientifically justified cleaning procedure with residue limits and validated methods1 |
| Sterile Drug Products Produced by Aseptic Processing — cGMP (2004) | U.S. FDA | Final rinse water for parenteral equipment should meet WFI specifications, and endotoxin load matters because parenterals must be nonpyrogenic8 |
| Compliance Program 7356.002A, Sterile Drug Process Inspections | U.S. FDA | Directs investigators to cleaning, WFI use and WFI system performance in sterile operations9 |
| Inspection technical guide: Bacterial Endotoxins/Pyrogens | U.S. FDA | Sets out the K/M endotoxin limit and accepted approaches to depyrogenation of equipment10 |
| EMA guideline on health-based exposure limits and PIC/S PI 046-1 | EMA / PIC/S | Defines the permitted daily exposure (PDE) approach for shared facilities2,3 |
The overall sequence is the same as for other dosage forms: define the procedure, choose the worst case, calculate limits, clean, sample, test, confirm with three successful runs, and document.15
03Responsibilities
| Function | Responsibility |
|---|---|
| Production | Executes the cleaning (usually CIP) and sterilization steps as written and records every parameter |
| Quality Control | Validates analytical methods, analyzes rinse and swab samples, runs endotoxin tests, reports results against limits |
| Microbiology | Performs bioburden and endotoxin testing, and advises on sanitization and hold times |
| Quality Assurance | Approves the protocol and report, handles deviations, owns the product matrix and revalidation triggers |
| Toxicology / EHS | Supplies or reviews the route-specific PDE for each active |
| Engineering | Provides drawings and surface areas, confirms spray coverage and the absence of dead legs, and owns CIP/SIP qualification |
04The validation procedure, step by step
Work through the ten steps in order. Click each to expand it.
List every product-contact item and group them into trains, for example compounding tank → sterilizing filter housing → holding tank → filling pump, tubing and needles → lyophilizer. Record each item's surface area in cm² from drawings.
- Include valves, gaskets, sampling ports, transfer lines and filter housings
- Confirm the equipment, CIP and SIP are qualified before cleaning validation starts
Build a product matrix with dose, route-specific PDE, batch volume, solubility, cleanability and the nature of the soil (a clear salt solution, a protein, a suspension). Worst-case products are typically those that are hardest to clean and most potent or toxic. Rate and select (section 07).
- Items that are high risk because of difficulty of cleaning or low MACO should be used as worst-case products or qualified separately11
- Reassess the worst case whenever a new product is introduced
Convert batch volume, density and dose volume into batch mass and number of daily doses (Equation 1), then calculate MACO by the health-based method using the PDE for the route of the next product, and where policy requires the dose-based and 10 ppm methods. Use the most stringent, convert it to surface and rinse limits, and derive the TOC and endotoxin limits (Equations 2 to 11).
- Use the smallest batch and the largest daily dose of the next product
- Set limits for cleaning agent, endotoxin and bioburden too
Combine swabs at worst-case locations such as valves, dead legs and rough welds with a final rinse for overall confirmation, since the combination gives the most comprehensive coverage. A rinse cannot detect localized contamination in dead legs or poor spray coverage areas.12 The final rinse is typically analyzed for TOC, conductivity, endotoxin and bioburden.12
- Define each location, the swab area (commonly 25 cm²), and the rinse volume and sampling point
- Test CIP spray coverage during development, for example with a riboflavin challenge14
Select a specific method such as HPLC, or a non-specific method such as TOC where justified, with a quantitation limit well below the rinse and swab limits. Conductivity detects trace cleaning chemicals during the WFI rinse, and the LAL assay measures endotoxin.11 The WFI used for the rinse has its own TOC and conductivity, so the method needs a proper blank.
- Validate each method for the matrix, which here is dilute WFI rinse
- See the analytical method validation posts earlier in this series
Spike known amounts of the worst-case active onto coupons of each surface material, recover them by the defined swab or rinse technique, and measure what comes back (Equation 7). Apply the recovery to later results (Equation 8).
- Include stainless steel, gaskets, tubing and filter housing materials
- For TOC, confirm that the spiked residue is recovered as carbon
The protocol fixes the products, equipment, cleaning and sterilization SOPs, limits, sampling locations, methods, hold times and acceptance criteria before any run. Quality approves it before execution.
- Acceptance criteria are never changed after the data is seen
- Define the investigation route for a failure
Manufacture the worst-case product, clean strictly per the SOP, inspect, sample and test. Repeat until three consecutive runs meet all criteria.15 Take bioburden and endotoxin samples at the end of the wash after a dirty hold time challenge, outside the normally allowed time before cleaning.13
- Cover the validated dirty and clean hold times
- Record everything contemporaneously
Correct each result for recovery, compare with the limit, and confirm the total carryover across the train is below MACO. The report states the conclusion, any deviations, and the products and equipment now covered.
- Any failure triggers an investigation and a root cause before more runs
Set up periodic verification, trending and revalidation triggers: a new product, a change in equipment, spray device, cleaning agent or cycle, or a failure. A new product re-evaluates the worst case and recalculates affected limits under change control.5
- For CIP, a change to flow, temperature, concentration or time changes the validated cycle
- Link to the change control and environmental monitoring posts earlier in this series
05Parenteral equipment and sampling locations
Each stage of sterile manufacture has its own hard-to-clean areas. Switch tabs to see typical locations, noting that the final list must come from your own risk assessment.
Compounding and holding tanks. Check spray device coverage, agitator seals, the outlet valve and the manway gasket. Swab at the worst-case spots such as valve seats, gasket grooves and rough welds, which rinse sampling cannot reliably detect.12
Filtration and transfer lines. Sterilizing filter housings, product lines, valves and gaskets carry product and need both swab and rinse coverage. Dead legs, where cleaning solution cannot penetrate, have to be designed out, since they are where a rinse is blind.12
Filling line. Pumps, product tubing and filling needles are the direct-contact parts. Where single-use tubing and filters are used, the cleaning scope shrinks to the reusable parts, but the product-contact surfaces that remain still need defined swab locations.
Lyophilizer. Partially stoppered vials are loaded into the chamber, so the shelves and chamber are product-adjacent surfaces. The area between the filling line and the lyophilizer is expected to provide ISO 5 protection.8,9 Include shelves, chamber walls and loading equipment in the plan.
Cleaning Validation: A Practical Approach — Destin A. LeBlanc
A practical guide to the complete cleaning validation workflow, from limit calculations and sampling choices to recovery studies, protocols and reports.
Its treatment of rinse and swab strategies and of non-specific methods such as TOC is the most relevant part here, because parenteral protocols lean on those methods more than any other dosage form in this series.
06The cleaning procedure itself
Validation tests a written SOP, so the SOP has to be specific enough to repeat. A parenteral equipment SOP, typically clean-in-place, follows this sequence.
- Drain. Completely drain residual product from tanks and lines, so cleaning starts from the smallest soil load.
- Pre-rinse. Rinse with WFI or purified water to remove gross product, sending it to waste.14
- Caustic or detergent wash. Circulate the cleaning agent at defined concentration, temperature, flow and contact time. Caustic is the main cleaning solution in many CIP cycles.14
- Intermediate rinse. Rinse with WFI or purified water to remove the cleaning agent.14
- Final rinse. Rinse with WFI, since for parenteral products the final rinse water should meet WFI specifications.8 Take the validation rinse sample here, and check conductivity to detect trace cleaning chemicals.11
- Drain and dry. Drain fully, and dry or flush as specified, because damp equipment supports growth of microbes and endotoxin.
- Inspect. Inspect all accessible surfaces, including valves, gaskets and sampling ports.
- Sterilize. Apply the validated steam-in-place or sterilization step. For equipment and transfer lines, depyrogenation by dilution has usually been the method of choice.10
- Release and label. Label as clean with date, time and cleaning record reference, and start the clean hold time.
The critical CIP parameters are temperature, flow rate or supply pressure, chemical concentration, chemical contact time and the final rinse.14 Each should be defined, controlled and monitored.
07Worst-case product selection
The worst-case previous product is the one hardest to clean and with the lowest residue limit. Rate each product on the factors below, add the ratings, and take the highest total.
| Product | Solubility in cleaning solution (5 = poor) | Toxicity / PDE (5 = lowest PDE) | Cleanability (5 = hardest) | Lowest batch ÷ largest daily dose (5 = lowest) | Total |
|---|---|---|---|---|---|
| Injection A (potent small molecule, low solubility) | 5 | 5 | 3 | 4 | 17 |
| Injection B (protein, foaming and sticky) | 3 | 3 | 5 | 3 | 14 |
| Injection C (simple salt solution) | 1 | 1 | 1 | 2 | 5 |
In this illustration the potent, poorly soluble active scores highest. A protein product can still be the cleaning worst case even with a milder PDE, which is why some programs qualify it separately rather than letting one product stand for the group.11 Scoring is a screening tool and needs a written rationale.
08Calculations and equations
Each equation has a worked example using one consistent scenario. Scenario: Product A (previous, worst case) has a parenteral PDE of 0.2 mg/day and a lowest standard daily dose of 5 mg. Product B (next) has a minimum batch of 500 L, a density of 1.0 kg/L and a maximum daily dose of 20 mL. The shared product-contact surface area is 40,000 cm², and the final rinse uses 100 L of WFI.
Batch volume to batch mass and number of daily doses
Vbatch = minimum batch volume, ρ = density (kg/L), Vday = maximum daily dose volume (mL/day).
Worked. MBS = 500 × 1.0 = 500 kg. ndoses = 500,000 mL / 20 mL = 25,000 daily doses per batch.
Health-based MACO (PDE method)
Use the PDE that corresponds to the route of exposure of the next product, here parenteral. This is the standard PDEA × MBSB / MDDB rewritten using Equation 1.2,3,4,5
Worked. MACO = 0.2 × 25,000 = 5,000 mg.
Dose-based MACO (1/1000 of the lowest dose)
STDA = lowest standard daily dose of the previous product (mg/day), SF = safety factor, traditionally 1000.4,5
Worked. MACO = 5 × 25,000 / 1000 = 125 mg.
10 ppm criterion
Ten parts per million is ten milligrams of residue per kilogram of the next product.4
Worked. MACO = 10 × 500 = 5,000 mg.
Selecting the limit
Use the most stringent value your policy allows. Where health-based limits are required, MACOPDE controls and the others are shown for comparison.2,3
Worked. The minimum of 5,000, 125 and 5,000 mg is 125 mg (dose-based).
Surface residue limit
Lsurface in µg/cm², MACO in mg, SSA = total shared surface area (cm²).5
Worked. 125 × 1000 / 40,000 = 3.125 µg/cm².
Rinse limit and rinse recovery
SSArinsed = surface area contacted by the rinse (cm²), Vrinse = total rinse volume (mL).
Worked. Crinse = 3.125 × 40,000 / 100,000 = 1.25 µg/mL. With 90% recovery the method should read 1.25 × 0.90 = 1.125 µg/mL at the limit.
Corrected residue from a rinse result
The product C × V is the total residue washed into the rinse. Compare the result with Lsurface from Equation 6.
Worked. A rinse reads 0.62 µg/mL. Residue = (0.62 × 100,000 × 100 / 90) / 40,000 = 1.72 µg/cm², which is 55% of the 3.125 µg/cm² limit. The total residue is about 69 mg, against a MACO of 125 mg.
Swab limit for worst-case locations
Swabs cover dead legs, valve seats and welds that a rinse can miss.12 The evaluation follows Equation 8 of the tablets post.
Worked. Lswab = 3.125 × 25 = 78.1 µg per swab. In 10 mL, Climit = 7.81 µg/mL.
TOC limits from the active residue limit
fC = carbon fraction of the active, nC = number of carbon atoms, MW = molecular weight. A common approach converts the surface limit to a TOC limit by multiplying by the carbon fraction of the target molecule.12 The rinse water's own TOC must be subtracted as a blank, and the limit must sit well above the water's background.
Worked. With fC = 0.50, TOCsurface = 3.125 × 0.50 = 1.56 µg C/cm² and TOCrinse = 1.25 × 0.50 = 0.625 mg/L.
Endotoxin limit for the next product (K/M)
K = 5 EU/kg for non-intrathecal parenteral products, M = maximum dose per kg per hour (mL/kg·h). FDA's guide shows 5 EU/kg divided by 10 mL/kg giving 0.5 EU/mL.10 Water for Injection has an allowable endotoxin limit of 0.25 EU/mL.10 Components that would contribute less than 5% of the product limit are low risk.13
Worked. M = 20 mL per hour / 70 kg = 0.286 mL/kg·h, so the limit is 5 / 0.286 = 17.5 EU/mL. A WFI final rinse at 0.25 EU/mL is 1.4% of that limit, comfortably below 5%.
Carryover check in the next product
Daily dose of B in grams = Vday (mL) × ρ (kg/L).
Worked. Cnext = 125 / 500 = 0.25 ppm. Daily dose = 20 × 1.0 = 20 g. Exposure = 0.25 × 20 = 5.0 µg/day, which is 2.5% of the 200 µg/day PDE and equals 1/1000 of the 5 mg standard dose.
Equipment train check
The total carryover across the whole train must stay below MACO, even if one location has more than average.6,7
09Interactive calculators
The defaults reproduce the worked example above. Change the inputs to see your own limits.
A. MACO, residue, TOC and swab limits interactive
Implements Equations 1 to 7, 9, 10 and 12, with batch size in litres and dose in mL.
B. Rinse result and endotoxin check interactive
Implements Equations 7, 8 and 11. If you enter spiked and recovered amounts, the calculated recovery is used. Otherwise the manual recovery field is used.
These calculators illustrate the arithmetic only. A real protocol uses toxicologist-derived, route-specific PDEs, qualified surface areas, validated methods, and acceptance criteria approved in advance. The endotoxin limit shown applies to non-intrathecal parenteral products, and intrathecal products use a much lower K.
Endotoxins: Pyrogens, LAL Testing and Depyrogenation — Kevin L. Williams (Ed.)
A reference in the Drugs and the Pharmaceutical Sciences series that covers endotoxin from a parenteral manufacturing perspective: its biology, LAL assay development and automation, depyrogenation, and risk assessment.
It supports the endotoxin side of this procedure directly, including how the K/M limit is applied and how depyrogenation of equipment is approached, which most general cleaning validation books treat only briefly.
10Acceptance criteria and hold times
| Parameter | Criterion | Basis |
|---|---|---|
| Visual | No visible residue on any accessible surface | Applied to every run and every surface |
| Active residue (rinse) | Concentration ≤ Crinse (Eq. 7); corrected residue ≤ Lsurface (Eq. 8) | Most stringent MACO, route-specific PDE |
| Active residue (swab) | Corrected residue ≤ Lsurface at worst-case locations | Same MACO, local basis |
| TOC | Rinse and swab TOC ≤ limit from Eq. 10, after blank correction | Non-specific method, justified by carbon fraction12 |
| Cleaning agent | Final WFI rinse conductivity within the defined limit | Detects trace cleaning chemicals11 |
| Endotoxin | Final rinse within the WFI specification, and within the K/M limit (Eq. 11) | Parenterals must be nonpyrogenic8,10 |
| Bioburden | Equal to or lower than the product specification for each process segment | Limit from the process stage11 |
| Train total | Σ residue × area ≤ MACO (Eq. 13) | Confirms overall carryover |
| Reproducibility | Three consecutive successful runs | Standard validation practice15 |
Hold times. Validate the maximum dirty equipment hold time and test bioburden and endotoxin at the end of the wash after a dirty hold beyond the normally allowed time.13 Validate the maximum clean equipment hold time too: equipment cleaned to the TOC limits should still meet bioburden and endotoxin limits after storage.11
11Checklist and pitfalls
Readiness checklist
- Using an oral PDE for an injectable. The limit should reflect the route of the product that will be exposed, so check which route's PDE the calculation uses.
- Setting a TOC limit below the water's background. If the limit is close to the TOC of the rinse water, the test cannot discriminate, so check the blank before fixing the limit.
- Relying on the rinse alone. A rinse averages across all surfaces and cannot find localized contamination in dead legs or poorly sprayed areas.12
- Ignoring endotoxin after a long hold. Equipment can pass chemical limits and still fail endotoxin and bioburden after a dirty or clean hold, so test them after the challenge.13
12Specimen quality forms
A protocol summary and a sampling and results record, ready to adapt to your own procedure.
Form CVP-01 — Cleaning Validation Protocol Summary (Parenterals)
Specimen only — not a controlled document.
| Item | Value | Calculation reference |
|---|---|---|
| Batch mass (kg) and daily doses per batch | Eq. 1 | |
| MACO (PDE / dose / 10 ppm) and selected | Eq. 2 to 5 | |
| Shared surface area (cm²) | Engineering drawings | |
| Surface limit (µg/cm²) and rinse limit (µg/mL) | Eq. 6, 7 | |
| Carbon fraction and TOC limits | Eq. 10 | |
| Endotoxin limit (EU/mL) and bioburden limit | Eq. 11 / protocol | |
| Dirty / clean hold times | Protocol |
Form CVP-02 — Sampling and Results Record
Specimen only — one row per sample, per run.
| Location or rinse point | Method | Active (µg/mL or µg/cm²) | TOC | Conductivity | Endotoxin (EU/mL) | Bioburden | Pass / Fail |
|---|---|---|---|---|---|---|---|
These specimen forms illustrate typical content only. Your quality system's document control procedure takes precedence over this format.
Validated Cleaning Technologies for Pharmaceutical Manufacturing — Destin A. LeBlanc
Explains how cleaning works: detergent chemistry, temperature, flow and contact time, and the design and control of automated and clean-in-place systems.
For injectables, where cleaning is almost always a CIP cycle followed by sterilization, it is the best reference for what makes a cycle capable and for the parameters worth monitoring and challenging in development runs.
13References
- U.S. Food and Drug Administration. Guide to Inspections of Validation of Cleaning Processes. July 1993. fda.gov
- gmp-compliance.org. "Shared and Dedicated Facilities: EMA Publishes Final Guideline on Setting Health Based Exposure Limits (PDEs)." gmp-compliance.org
- Pharmaceutical Inspection Co-operation Scheme. Guideline on Setting Health Based Exposure Limits … in Shared Facilities, PI 046-1. picscheme.org
- CASRAI. "Cleaning Validation: Worst-Case Grouping, MACO, and Acceptance Limits." casrai.org
- Leucine. "MACO Calculation in Cleaning Validation: A Complete Guide." leucine.ai
- Indian Pharmaceutical Alliance, Sub-Group 4. "Cleaning Methodology and Validation Best Practices Document." ipa-india.org
- APIC. "Guidance on Aspects of Cleaning Validation in Active Pharmaceutical Ingredient Plants." 2021. apic.cefic.org
- U.S. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. fda.gov
- U.S. Food and Drug Administration. Compliance Program 7356.002A: Sterile Drug Process Inspections. fda.gov
- U.S. Food and Drug Administration. Inspection Technical Guide: Bacterial Endotoxins/Pyrogens. fda.gov
- BioPharm International. "Risk-Based Cleaning Validation in Biopharmaceutical API Manufacturing." biopharminternational.com
- Bioprocess Tools. "Cleaning Validation for Biopharmaceutical Manufacturing: MACO Calculation, Sampling, and Acceptance Limits." bioprocesstools.com
- Biopharma Asia. "Endotoxin Control Strategies for Parenteral Drug Product Manufacturing." biopharma-asia.com
- Wikipedia. "Clean-in-place." en.wikipedia.org
- PharmaGMP Guide. "Cleaning Validation in Pharma: 10 Proven Steps, Complete SOP, MACO Calculation Guide." pharmagmpguide.com
No comments:
Post a Comment